The US Food and Drug Administration (FDA) has approved the obesity treatment tirzepatide (Zepbound, Eli Lilly) for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity.
Miriam E. Tucker is a Contributing Writer at various esteemed publications, including MDEdge and Medscape. She specializes in medicine and healthcare, with a particular focus on topics such as nutrition, diagnostics, and wellness, while also exploring the impact of healthcare systems and alternative medicine. Miriam has been featured in prominent platforms like The diaTribe Foundation and Guidelines Co, bringing her extensive knowledge as someone living with type 1 diabetes since 1973 to her writing.